Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients

HIV Medicine

Volumn 10, Issue 9, 2009, Pages 580-585

  Cesari, M ^a   Caramma, I ^a   Antinori, S ^a   Adorni, F ^b   Galli, M ^a   Milazzo, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Cholesterol levels; HIV HCV coinfection; Hyperglycaemia; Sustained virological response

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTIVIRAL AGENTS; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; INTERFERON ALFA-2B; LIPODYSTROPHY; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; TRIGLYCERIDES; VIRAL LOAD;

EID: 70349997498     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00729.x     Document Type: Article

References (30)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
2. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia. J Hepatol 2001, 34:428-434.
3. Fernández-Rodríguez CM, López-Serrano P, Alonso S. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006, 24:507-512.
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Ann Intern Med 2000, 133:592-599.
5. Mehta SH, Brancati FL, Strathdee SA. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
6. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006, 12:7075-7080.
7. Romero-Gomez M, Dek Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
8. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008, 48:721-727.
9. Kawaguchi T, Ide T, Taniguchi E. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102:570-576.
10. Graham I, Atar D, Borch-Johnsen K. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2007, 28:2375-2414.
11. Galli M, Polo R, Saint-Marc T. Proposal for a clinic classification of morphological and metabolic alterations under ART. Antiviral Ther 2000, 5((Suppl. 5)):57. for the ART-Associated Lipodystrophy European Collaborative Study (ALECS) Group., Abstract P58
12. Sterling RK, Lissen E, Clumeck N. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
13. Nasta P, Gatti F, Puoti M. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008, 22:857-861.
14. Gopal K, Johnson TC, Gopal S. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006, 44:335-340.
15. Akuta N, Suzuki F, Kawamura Y. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype. J Hepatol 2007, 46:403-410.
16. Torriani FJ, Rodriguez-Torres M, Rockstroh JK. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
17. Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes. Quart J Med 2005, 98:1-6.
18. Kawaguchi T, Yoshida T, Harada M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:1499-1508.
19. Dharancy S, Malapel M, Perlemuter G. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005, 128:334-342.
20. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers. Diabetes Res Clin Pract 2007, 75:320-326.
21. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV. Intern Emerg Med 2008, 3:99-108.
22. Wand H, Calmy A, Carey DL. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
23. Lo JC, Kazemi MR, Hsue PY. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005, 41:1335-1340.
24. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
25. Lapadula G, Torti C, Paraninfo G. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006, 11:521-527.
26. Bedimo R, Ghurani R, Nsuami M. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 2006, 7:530-536.
27. Galli M, Cozzi-Lepri A, Ridolfo AL. Incidence of adipose tissue alterations in first-line antiretroviral therapy. Arch Intern Med 2002, 162:2621-2628.
28. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997, 157:792-796.
29. Agnello V, Abel G, Elfahal M, Knight GB, Zhang OX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999, 96:12766-12771.
30. André P, Komurian-Pradel F, Deforges S. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002, 76:6919-6928.